All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
TORONTO – Calgary, Alberta-based Orpyx Medical Technologies Inc. has launched a sensory insole with remote patient monitoring to prevent potentially fatal diabetic foot ulcers (DFU) and neuropathy-related ulcers. According to Orpyx CEO Breanne Everett, development of the Orpyx SI sensory insole system follows years of study on how DFUs occur and how best to share information with patients and doctors so they can react quickly to first signs of the condition.
In its first step into Japan, Agex Therapeutics Inc. accelerates its development of engineering hypoimmunogenic cells, universal cells that can be used on patients who didn’t generate the original cell and without the need to use immunosuppressants.
When they work, T cells work great. And the folks at Avidea Technologies Inc. want to make them work more often. Combining expertise in immunology and polymer chemistry, the Baltimore-based startup is developing antigen delivery technology to improve T cell-targeted vaccines.
Kintai Therapeutics Inc. CEO, president and board member Paul-Peter Tak told BioWorld that the company aims to reach the clinic in the first quarter of next year with obesity agent KTX-0200, which has begun IND-enabling studies after showing sustained weight loss and improved markers of health in preclinical experiments.
Boulder, Colo.-based startup Arpeggio Biosciences Inc. scooped up $3.2 million in seed funding in a round led by Khosla Ventures, with participation by Fundersclub, Fifty Years, TechU and Y Combinator.
Not only did newly emergent Kyverna Therapeutics Inc. burst out of the gate with a $25 million series A, but it enhanced its entrance with a deal from Gilead Sciences Inc., one of the company’s initial funders, potentially worth $587.5 million.
Boulder, Colo.-based startup Arpeggio Biosciences Inc. scooped up $3.2 million in seed funding in a round led by Khosla Ventures, with participation by Fundersclub, Fifty Years, TechU and Y Combinator.
HONG KONG – South Korean biopharma Genesen Inc. has secured ₩2.2 billion (US$1.9 million) in seed funding to advance its peptide-based drug candidates for the treatment of autoimmune and inflammatory diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis and psoriasis.
When Zebiai Therapeutics Inc.’s CEO, Rick Wagner, went about naming his new machine learning company, he wanted it to connote something dramatic that displayed the company’s potential to reach into the seemingly boundless future technology had unlocked.
HONG KONG – South Korean biopharma Genesen Inc. has secured ₩2.2 billion (US$1.9 million) in seed funding to advance its peptide-based drug candidates for the treatment of autoimmune and inflammatory diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis and psoriasis.
HONG KONG – South Korea’s Ministry of Food and Drug Safety (MFDS) recently granted the first urgent-use licenses to four COVID-19 novel coronavirus diagnostic...
As the COVID-19 outbreak continues to dominate the news, an increasing number of companies have come forward to help. For its part, CHF Solutions Inc., of Eden...
BEIJING – Beijing-based Sihuan Pharmaceutical Holdings Group Ltd. said it has initiated clinical trials of broad-spectrum antiviral favipiravir to treat COVID-19....
Mallinckrodt plc is engaging with the U.S. FDA, NIH and the Biomedical Advanced Research and Development Authority to address the potential use of its INOmax...
HONG KONG – As the number of COVID-19 confirmed cases and deaths continue to rise globally, South Korea’s focus on testing has attracted international attention....
BioWorld Premium
Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.
RSS
